References
Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26(2):225-39. Jun.
Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82(10):699-757. Oct.
Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med. 2007;37(6):451-61. Nov.
Vāvere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;21(43):4893-902. Nov.
Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46(1):106-13. Jan.
Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol. 2007;17(4):861-72. Apr.
Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)f-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):235-42. Jan 1.
Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, et al. Hypoxia-imaging with [18F]-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83(3):406-10. Jun.
Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007;68(2):515-21. Jun 1.
Grigsby PW, Malyapa RS, Higashikubo R, Schwarz JK, Welch MJ, Huettner PC, et al. Comparison of molecular markers of hypoxia and imaging with 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol. 2007;9(5):278-83. Sep-Oct.
Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34(10):1566-75. Oct.
Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):541-51. Oct 1.
Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70(1):2-13. Jan 1.
Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA—first small animal PET results. J Pharm Pharm Sci. 2007;10(2):203-11.
Lecchi M, Fossati P, Elisei F, Orecchia R, Lucignani G. Current concepts on imaging in radiotherapy. Eur J Nucl Med Mol Imaging. 2007; DOI 10.1007/s00259-007-0631-y, Oct 31; [Epub ahead of print].
Krause BJ, Beck R, Souvatzoglou M, Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging. 2006;50(1):28-43. Mar.
Author information
Authors and Affiliations
Corresponding author
Additional information
This commentary derives from a literature search of recently published articles and draws extensively on the texts of the articles referenced.
An Erratum for this chapter can be found at http://dx.doi.org/10.1007/s00259-008-0764-7
Rights and permissions
About this article
Cite this article
Lucignani, G. PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging 35, 838–842 (2008). https://doi.org/10.1007/s00259-008-0740-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-008-0740-2